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zoal parasites of the genus Plasmodium (with P. falci-
parum the cause of fatal cases) [5]. They have a complex
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Discovering Antimalarials:
a New Strategy life cycle involving liver and blood stages in the human
host, where asexual reproduction occurs, and a stage
in the vector mosquito (Anopheles genus), where sexual
Recent discoveries have uncovered some key pro- reproduction occurs [5]. Symptoms and pathology are
cesses that occur in the food vacuole of the malarial associated entirely with the blood stage, during which
parasite. Consequently, new families of potential anti- the parasite is located within the red blood cell of the
malarials that inhibit HRP-2, a hitherto unexplored host [5]. During this part of the life cycle, the parasite
drug target, were identified using a novel screening ingests hemoglobin into a specialized acidic compart-
method. ment called a food vacuole. The hemoglobin is proteolyt-
ically digested into small peptides that ultimately supply
Malaria is one of the world’s leading killer infectious the parasite with amino acids [6] (although intriguingly,
diseases. Although almost a third of the Earth’s popula- these nutrients appear to be oversupplied [7]). Proteoly-
tion is considered to be at risk from this disease, about sis is carried out by four aspartic proteases, namely
90% of infections and deaths occur in Africa [1], contrib- plasmepsins I, II, and IV, and histo-aspartic protease
uting significantly to underdevelopment and poverty on (HAP) [8], three cysteine proteases (falcipains) [9], and
this continent [2]. The reasons for the current severity a zinc protease (falcilysin) [10]. All of these represent
of the malaria problem are multifaceted, but among them potential targets for antimalarials (see Figure) and are
is the occurrence of drug-resistant strains of parasite. currently the subject of intense investigation. Digestion
Most notable in this regard is parasite resistance to of hemoglobin releases heme [iron(II)protoporphyrin IX,
chloroquine, which is now almost universal. In the past, Fe(II)PPIX] into the food vacuole, where it is oxidized to
this drug, having several excellent properties, became hematin [H2O-Fe(III)PPIX] [6]. Heme is another possible
the mainstay of treatment and was a key component of drug target and has been implicated in the mode of
malaria control strategies. In particular, chloroquine was action of endoperoxide antimalarials, such as artemes-
highly effective against the parasite, had very few ad- inin, which have been proposed to form radical adducts
verse side effects, was safe for use in pregnancy and with heme that act against the parasite [11]. Hematin
young children, and was very cheap [3]. Its loss has is believed to be the target of chloroquine and other
been a major setback [4]. The challenge now is to find quinoline antimalarials, and there is evidence sug-
new compounds with antimalarial activity that can be gesting that these drugs act by preventing the detoxifi-
developed into drugs that are cheap enough for use in cation of hematin (see Figure) [12], essentially all of
poor third world countries. which is normally converted to a very insoluble micro-
A positive development over the last decade has been crystalline dimer of Fe(III)PPIX called hemozoin (or ma-
the considerable increase in our understanding of pro- laria pigment) [13]. Chemically, hemozoin is identical
in composition [14] and structure [15] to -hematin, acesses occurring within the parasite that are relevant to
the mode of action of current antimalarials and which synthetic product that can easily be prepared from a
solution of hematin.provide targets or potential targets for new antimalarial
compounds. The causative agents of malaria are proto- The mechanism of hemozoin formation in the parasite
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Drug Targets in the Food Vacuole of the Ma-
laria Parasite
Key pathways in the degradation of hemoglo-
bin and the detoxification of heme are shown.
Bold arrows and bars indicate drug targets,
with drug classes shown in boxes. Protein tar-
gets are given in italics. HRP-2 (histidine-rich
protein 2) is believed to initiate or catalyze he-
mozoin formation and is the target of a new
strategy for antimalarial drug discovery re-
ported in this issue of Chemistry & Biology
[20].
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